Supplementary Figure 7 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393928.v1

2023-01-01

Abstract:PDF file - 288K, The binding of NRF2 to the ARE sites in MCF7 and MCF7-RXRo cells.

What problem does this paper attempt to address?

Supplementary Figure 6 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393931

2023-01-01

Abstract:PDF file - 239K, The interaction of mNrf2 with RXRa in MCF7-RXRa cells.
Supplementary Figure 3 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393940

2023-01-01

Abstract:PDF file - 188K, RXRa interacted with Nrf2 in vivD.
Supplementary Figure 4 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393937

2023-01-01

Abstract:PDF file - 160K, tBHQ increased the expression of AKR1C in MCF7 cells.
Supplementary Figure 2 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393943

2023-01-01

Abstract:PDF file - 572K, Cellular co-localization of ectopic GFP and RFP in HEK293T cells.
Supplementary Figure 5 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393934

2023-01-01

Abstract:PDF file - 232K, BHA up-regulated ARE-gene battery in mouse small intestine and liver.
Supplementary Figure 1 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393946

2023-01-01

Abstract:PDF file - 499K, Recombinant his-RXRa was unable to interact with GST-hNRF2 mutant fusion protein that lacked residues 209-316 between the Neh5 and Neh6 domains.
Supplementary Methods from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393922

2023-01-01

Abstract:PDF file - 97K, Includes plasmid construction data, GST pull-down assay, and immunoprecipitation data. Also includes supplementary references.
RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.can-12-3386

IF: 11.2

2013-01-01

Cancer Research

Abstract:AbstractThe transcription factor NRF2 (NFE2L2) is a pivotal activator of genes encoding cytoprotective and detoxifying enzymes that limit the action of cytotoxic therapies in cancer. NRF2 acts by binding antioxidant response elements (ARE) in its target genes, but there is relatively limited knowledge about how it is negatively controlled. Here, we report that retinoic X receptor alpha (RXRα) is a hitherto unrecognized repressor of NRF2. RNAi-mediated knockdown of RXRα increased basal ARE-driven gene expression and induction of ARE-driven genes by the NRF2 activator tert-butylhydroquinone (tBHQ). Conversely, overexpression of RXRα decreased ARE-driven gene expression. Biochemical investigations showed that RXRα interacts physically with NRF2 in cancer cells and in murine small intestine and liver tissues. Furthermore, RXRα bound to ARE sequences in the promoters of NRF2-regulated genes. RXRα loading onto AREs was concomitant with the presence of NRF2, supporting the hypothesis that a direct interaction between the two proteins on gene promoters accounts for the antagonism of ARE-driven gene expression. Mutation analyses revealed that interaction between the two transcription factors involves the DNA-binding domain of RXRα and a region comprising amino acids 209-316 in human NRF2 that had not been defined functionally, but that we now designate as the NRF2-ECH homology (Neh) 7 domain. In non–small cell lung cancer cells where NRF2 levels are elevated, RXRα expression downregulated NRF2 and sensitized cells to the cytotoxic effects of therapeutic drugs. In summary, our findings show that RXRα diminishes cytoprotection by NRF2 by binding directly to the newly defined Neh7 domain in NRF2. Cancer Res; 73(10); 3097–108. ©2013 AACR.
Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Jiaguo Wu,Hongyan Wang,Xiuwen Tang

DOI: https://doi.org/10.1016/j.bbrc.2014.08.111

IF: 3.1

2014-01-01

Biochemical and Biophysical Research Communications

Abstract:NF-E2 P45-related factor 2 (Nrf2) is a key transcription factor that controls genes encoding cytoprotective and detoxifying enzymes through antioxidant response elements (AREs) in their regulatory regions. We reported recently that retinoid X receptor alpha (RXR alpha) inhibits Nrf2 function by direct interaction with the Neh7 domain of Nrf2 in a ligand-independent manner. Here, we provide evidence that an RXR alpha-specific ligand, bexarotene, dose-dependently inhibits the mRNA expression of ARE-driven genes. Knock-down of RXR alpha by siRNA abolished the inhibitory effect of bexarotene. Conversely, the overexpression of RXR alpha enhanced the inhibition by bexarotene, indicating that the effect is mediated by RXR alpha. The inhibition by bexarotene was also found in the non-small-cell lung cancer cell line A549, which carries a dysfunctional somatic mutation of Kelch-like ECH-associated protein 1 (KEAP1), suggesting that KEAP1 is not involved. Our results demonstrate that rexinoid is able to inhibit the transcriptional activity of Nrf2, and that RXR alpha can repress the cytoprotection pathway in a ligand-dependent manner. (C) 2014 Elsevier Inc. All rights reserved.
Structural Basis for Retinoic X Receptor Repression on the Tetramer

Haitao Zhang,Lili Chen,Jing Chen,Hualiang Jiang,Xu Shen

DOI: https://doi.org/10.1074/jbc.M111.245498

IF: 5.485

2011-01-01

Journal of Biological Chemistry

Abstract:Retinoic X receptor (RXR) is a master nuclear receptor in the processes of cell development and homeostasis. Unliganded RXR exists in an autorepressed tetramer, and agonists can induce RXR dimerization and coactivator recruitment for activation. However, the molecular mechanisms involving the corepressor recruitment and antagonist-mediated repression of RXR are still elusive. Here we report the crystal structure of RXRα ligand-binding domain (LBD) complexed with silencing mediator for retinoid and thyroid hormone receptors (SMRT) corepressor motif. As the first structural report on the unliganded nuclear receptor bound to the corepressor motif, RXRαLBD-SMRT exhibits a significant structural rearrangement, compared with apoRXRαLBD tetramer. To elucidate further the molecular determinants for RXR repression by its antagonist, we also determine the crystal structure of RXRαLBD-SMRT complexed with the identified antagonist rhein. In the structure, two rhein molecules and two SMRT peptides are in the RXRαLBD tetramer, different from the case in RXRαLBD-SMRT structure, where four SMRT peptides bind to RXRαLBD tetramer. It seems that rhein induces a displacement of SMRT motif by activation function 2 (AF-2) motif binding to the receptor. Combining our current work with the published results, structural superposition of RXRαLBDs in different states reveals that RXR uses an overlapped binding site for coactivator, corepressor, and AF-2 motifs, whereas the AF-2 motif adopts different conformations for agonist or antagonist interaction and coactivator or corepressor recruitment. Taken together, we thus propose a molecular model of RXR repression on the tetramer.
Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Xiu Jun Wang,John D. Hayes,Colin J. Henderson,C. Roland Wolf

DOI: https://doi.org/10.1073/pnas.0709483104

2007-01-01

Abstract:Isothiocyanates and phenolic antioxidants can prevent cancer through activation of Nrf2 (NF-E2 p45-related factor 2), a transcription factor that controls expression of cytoprotective genes through the antioxidant response element (ARE) enhancer. Using a human mammary MCF7-derived AREc32 reporter cell line, we now report that all-trans retinoic acid (ATRA), and other retinoic acid receptor alpha (RARalpha) agonists, markedly reduces the ability of Nrf2 to mediate induction of ARE-driven genes by cancer chemopreventive agents including the metabolite of butylated hydroxyanisole, tert-butylhydroquinone (tBHQ). The basal and tBHQ-inducible expression of aldo-keto reductase (AKR) AKR1C1 and AKR1C2 genes, which are regulated by Nrf2, was also repressed by ATRA in AREc32 cells. Antagonists of RARalpha augmented induction of ARE-driven gene expression by tBHQ, as did knockdown of RARalpha by using RNAi. The expression of the ARE-gene battery was increased in the small intestine of mice fed on a vitamin A-deficient diet, and this increase was repressed by administration of ATRA. By contrast, in the small intestine of Nrf2 null mice, the expression of ARE-driven genes was not affected by vitamin A status. In MCF7 cells, ATRA did not block the nuclear accumulation of Nrf2 but reduced the binding of Nrf2 to the ARE enhancer as a consequence of forming a complex with RARalpha. These data suggest that cross-talk between Nrf2 and RARalpha could markedly influence the sensitivity of cells to electrophiles and oxidative stressors and, as a consequence, to carcinogenesis.
Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Xiu Jun Wang,John D. Hayes,C. Roland Wolf

DOI: https://doi.org/10.1158/0008-5472.22366175

2023-01-01

Abstract:Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents
The Short Isoform of PML‐RARα Activates the NRF2/HO‐1 Pathway Through a Direct Interaction with NRF2

Yulong Li,Hongyan Wang,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1002/1873-3468.12779

2017-01-01

FEBS Letters

Abstract:The NF‐E2 p45‐related factor 2 (NRF2)–Kelch‐like ECH‐associated protein 1 signaling pathway plays an important role in cytoprotection. In acute promyelocytic leukemia, fusion of the promyelocytic leukemia protein (PML) with retinoic acid receptor alpha (RARα) results in an oncogene, PML‐RARα (PR). Although previous studies have shown that both RARα and PML inhibit NRF2 activity, how PR regulates NRF2 has not been reported. Here, we discovered that PR‐S, the short isoform of PR, potentiates NRF2 activity in a tert‐butylhydroquinone (tBHQ) concentration‐dependent manner. Furthermore, PR‐S colocalized with NRF2 in HeLa and HEK293T cells. The association of PR‐S and NRF2 is mediated by the DNA‐binding domains of RARα and the Neh7 domain of NRF2. Our results define a novel function of PR‐S as a NRF2‐transcriptional co‐activator.
Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.

Akhileshwar Namani,Yulong Li,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1016/j.bbamcr.2014.05.003

IF: 5.011

2014-01-01

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Abstract:Nuclear factor-erythroid 2 p45-related factor 2 (NRF2, also known as Nfe2l2) plays a critical role in regulating cellular defense against electrophilic and oxidative stress by activating the expression of an array of antioxidant response element-dependent genes. On one hand, NRF2 activators have been used in clinical trials for cancer prevention and the treatment of diseases associated with oxidative stress; on the other hand, constitutive activation of NRF2 in many types of tumors contributes to the survival and growth of cancer cells, as well as resistance to anticancer therapy. In this review, we provide an overview of the NRF2 signaling pathway and discuss its role in carcinogenesis. We also introduce the inhibition of NRF2 by nuclear receptors. Further, we address the biological significance of regulation of the NRF2 signaling pathway by nuclear receptors in health and disease. Finally, we discuss the possible impact of NRF2 inhibition by nuclear receptors on cancer therapy.
Generation of A Stable Antioxidant Response Element-Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Xiu Jun Wang,John D. Hayes,C. Roland Wolf

DOI: https://doi.org/10.1158/0008-5472.can-06-2298

IF: 11.2

2006-01-01

Cancer Research

Abstract:Abstract The NF-E2 p45-related factor 2 (Nrf2) regulates cytoprotective genes that contain an antioxidant response element (ARE) in their promoters. To investigate whether anticancer drugs can induce ARE-driven gene expression, we have developed a stable human mammary MCF7-derived reporter cell line called AREc32, which contains a luciferase gene construct controlled by eight copies of the cis-element. In these cells, luciferase activity was increased up to 50-fold following treatment with 50 μmol/L tert-butylhydroquinone (t-BHQ). Basal and inducible luciferase activities in AREc32 cells were increased by forced overexpression of Nrf2 and reduced by knockdown of endogenous Nrf2 expression with RNA interference. Depletion of cellular reduced glutathione (GSH) by treatment of AREc32 cells with l-buthionine-S,R-sulfoximine (BSO) did not influence basal levels of luciferase activity, but pretreatment with BSO augmented induction of luciferase activity by t-BHQ. Induction of reporter activity by t-BHQ in AREc32 cells was suppressed markedly by the antioxidants N-acetylcysteine and GSH but only modestly by vitamins C or E, suggesting that ARE-luciferase expression is induced primarily by thiol-active electrophiles rather than free radicals. The anticancer drugs cisplatin, etoposide, mitoxantrone, chlorambucil, melphalan, and carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)] weakly induced luciferase activity in AREc32 cells. Moreover, treatment of AREc32 cells with BSO immediately before exposure to anticancer drugs enhanced induction of ARE-driven luciferase activity by cisplatin, BCNU, chlorambucil, and melphalan and also induced endogenous AKR1C (AKR1C refers to AKR1C1 and AKR1C2), a target gene of Nrf2. Our findings show that Nrf2 can be activated by certain anticancer agents, and this will influence the effectiveness of chemotherapy. (Cancer Res 2006; 66(22): 10983-94)
Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Akhileshwar Namani,Kaihua Liu,Shengcun Wang,Xihang Zhou,Yijiao Liao,Hongyan Wang,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.18632/aging.102590

2019-01-01

Aging

Abstract:Nuclear factor erythroid-derived-2-like 2(NRF2) regulates its downstream genes through binding with antioxidant responsive elements in their promoter regions. Hyperactivation of NRF2 results in oncogenesis and drug resistance in various cancers including non-small cell lung cancer (NSCLC). However, identification of the genes and pathways regulated by NRF2 in NSCLC warrants further investigation. We investigated the global NRF2 genomic binding sites using the high-throughput ChIP-Seq technique in KEAP1 (Kelch-like ECH-associated protein 1)-mutated A549 (NSCLC) cells. We next carried out an integrated analysis of the ChIP-Seq data with transcriptomic data from A549 cells with NRF2-knockdown and RNA-Seq data from TCGA patients with altered KEAP1 to identify downstream and clinically-correlated genes respectively. Furthermore, we applied transcription factor enrichment analysis, generated a protein-protein interaction network, and used kinase enrichment analysis. Moreover, functional annotation of NRF2 binding sites using DAVID v7 identified the genes involved in focal adhesion. Putative focal adhesion genes regulated by NRF2 were validated using qRT-PCR. Further, we selected one novel conserved focal adhesion gene regulated by NRF2-LAMC1 (laminin subunit gamma 1) and validated it using a reporter assay. Overall, the identification of NRF2 target genes paves the way for identifying the molecular mechanism of NRF2 signaling in NSCLC development and therapy. Moreover, our data highlight the complexity of the pathways regulated by NRF2 in lung tumorigenesis.
Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

Xiuwen Tang,Hongyan Wang,Longfang Fan,Xiaoyuan Wu,Ai Xin,Huanyu Ren,Xiu Jun Wang

DOI: https://doi.org/10.1016/j.freeradbiomed.2011.03.008

2011-01-01

Abstract:Nuclear factor erythroid 2-related factor 2 (Nrf2) is a redox-sensitive transcription factor regulating the expression of a battery of cytoprotective genes. Constitutive Nrf2 activation in many tumors enhances cell survival and resistance to anticancer drugs. Using a cell-based ARE-reporter assay we discovered that the flavonoid luteolin is a potent Nrf2 inhibitor. Luteolin inhibited ARE-driven gene expression redox-independently. In non-small-cell lung cancer A549 cells, which possess constitutively active Nrf2, luteolin elicited a dramatic reduction in Nrf2 at both the mRNA and the protein levels, leading to decreased Nrf2 binding to AREs, down-regulation of ARE-driven genes, and depletion of reduced glutathione. After transcription was blocked with actinomycin D, 1μM luteolin decreased the Nrf2 mRNA level by 34% in 30min, indicating its role in accelerating Nrf2 mRNA turnover. At physiological concentrations, luteolin significantly sensitized A549 cells to the anticancer drugs oxaliplatin, bleomycin, and doxorubicin. However, knockdown of Nrf2 using siRNA essentially abolished the induced sensitivity by the flavonoid, implying the importance of inhibiting Nrf2 for its activity. Our study demonstrates that an Nrf2 inhibitor can enhance the responsiveness of cancer cells to chemotherapeutic drugs and indicates the potential application of luteolin as a natural sensitizer in chemotherapy.
Supplementary Data from Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Wenjie You,Lijun Li,Deqiao Sun,Xueqing Liu,Zongjun Xia,Shan Xue,Bi Chen,Hui Qin,Jing Ai,Handong Jiang

DOI: https://doi.org/10.1158/2326-6066.22539082

2023-01-01

Abstract:Supplementary Table 1, Supplementary Figures 1-7
Retinoid X Receptor Regulates Nur77/TR3-Dependent Apoptosis by Modulating Its Nuclear Export and Mitochondrial Targeting

Xihua Cao,Wen Liu,Feng Lin,Hui Li,Siva Kumar Kolluri,Bingzhen Lin,Young-hoon Han,Marcia I. Dawson,Xiao-kun Zhang

DOI: https://doi.org/10.1128/MCB.25.1.524.2005

IF: 5.069

2005-01-01

Molecular and Cellular Biology

Abstract:Retinoid X receptor (RXR) plays a central role in the regulation of intracellular receptor signaling pathways by acting as a ubiquitous heterodimerization partner of many nuclear receptors, including the orphan receptor Nur77 (also known as thyroid hormone receptor 3 or NGFI-B), which translocates from the nucleus to mitochondria, where it interacts with Bcl-2 to induce apoptosis. Here, we report that RXR is required for nuclear export and mitochondrial targeting of Nur77 through their unique heterodimerization that is mediated by dimerization interfaces located in their DNA-binding domain. The effects of RXR are attributed to a putative nuclear export sequence (NES) present in its carboxyl-terminal region. RXR ligands suppress NES activity by inducing RXR homodimerization or altering RXR/Nur77 heterodimerization. The RXR NES is also silenced by RXR heterodimerization with retinoic acid receptor or vitamin D receptor. Consistently, we were able to show that the mitochondrial targeting of the RXR/Nur77 heterodimer and its induction of apoptosis are potently inhibited by RXR ligands. Together, our results reveal a novel nongenotropic function of RXR and its involvement in the regulation of the Nur77-dependent apoptotic pathway.
Supplementary Figure 3 from TPCA-1 is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers

Jing Nan,Yuping Du,Xing Chen,Qifeng Bai,Yuxin Wang,Xinxin Zhang,Ning Zhu,Jing Zhang,Jianwen Hou,Qin Wang,Jinbo Yang

DOI: https://doi.org/10.1158/1535-7163.22499632.v1

2023-01-01

Abstract:EGFR silence inhibits STAT3 activation in MDA-MB-231 cells.

Supplementary Figure 7 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 6 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 3 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 4 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 2 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 5 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 1 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Methods from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

The Short Isoform of PML‐RARα Activates the NRF2/HO‐1 Pathway Through a Direct Interaction with NRF2

Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.

Generation of A Stable Antioxidant Response Element-Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

Supplementary Data from Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Retinoid X Receptor Regulates Nur77/TR3-Dependent Apoptosis by Modulating Its Nuclear Export and Mitochondrial Targeting

Supplementary Figure 3 from TPCA-1 is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers